Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Shattuck Labs Inc (STTK)

Shattuck Labs Inc (STTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 293,619
  • Shares Outstanding, K 63,280
  • Annual Sales, $ 5,720 K
  • Annual Income, $ -75,410 K
  • EBIT $ -58 M
  • EBITDA $ -56 M
  • 60-Month Beta 1.53
  • Price/Sales 261.17
  • Price/Cash Flow N/A
  • Price/Book 3.03

Options Overview Details

View History
  • Implied Volatility 146.64% (-831.71%)
  • Historical Volatility 77.77%
  • IV Percentile 10%
  • IV Rank 10.87%
  • IV High 978.35% on 01/15/26
  • IV Low 45.22% on 10/16/25
  • Expected Move (DTE 33) 0.43 (9.16%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 852
  • Volume Avg (30-Day) 116
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 992
  • Open Int (30-Day) 632
  • Expected Range 4.22 to 5.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.12
  • Number of Estimates 4
  • High Estimate -0.10
  • Low Estimate -0.15
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +67.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.82 +64.38%
on 12/18/25
4.89 -5.11%
on 01/08/26
+1.70 (+57.82%)
since 12/16/25
3-Month
1.72 +169.77%
on 11/14/25
4.89 -5.11%
on 01/08/26
+2.84 (+157.78%)
since 10/16/25
52-Week
0.69 +570.33%
on 04/07/25
4.89 -5.11%
on 01/08/26
+3.55 (+325.69%)
since 01/16/25

Most Recent Stories

More News
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development...

STTK : 4.64 (+3.80%)
Shattuck Labs to Participate in Upcoming December Investor Conferences

AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development...

STTK : 4.64 (+3.80%)
Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights

–First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers – – Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 – ...

STTK : 4.64 (+3.80%)
Shattuck Labs (STTK) Gets a Hold from Citi

In a report released today, Yigal Nochomovitz from Citi maintained a Hold rating on Shattuck Labs, with a price target of $2.00. The company’s shares closed today at $1.84.Elevate Your Investing Strategy:...

STTK : 4.64 (+3.80%)
Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel

AUSTIN, TX and DURHAM, NC, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis...

STTK : 4.64 (+3.80%)
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease —...

IRON : 70.93 (-0.15%)
STTK : 4.64 (+3.80%)
Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases – –...

STTK : 4.64 (+3.80%)
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 – – On track to dose first participant...

STTK : 4.64 (+3.80%)
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease – – Pro forma...

STTK : 4.64 (+3.80%)
Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

STTK : 4.64 (+3.80%)

Business Summary

Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company's wholly owned program includes SL-172154. It operates principally in Durham, North...

See More

Key Turning Points

3rd Resistance Point 5.08
2nd Resistance Point 4.88
1st Resistance Point 4.76
Last Price 4.64
1st Support Level 4.44
2nd Support Level 4.24
3rd Support Level 4.12

See More

52-Week High 4.89
Last Price 4.64
Fibonacci 61.8% 3.29
Fibonacci 50% 2.79
Fibonacci 38.2% 2.30
52-Week Low 0.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar